Invivyd, Inc. (NASDAQ: IVVD)

Sector: Healthcare Industry: Biotechnology CIK: 0001832038
Market Cap 320.96 Mn
P/B 3.45
P/E -5.36
P/S 6.41
ROIC (Qtr) -87.96
Div Yield % 0.00
Rev 1y % (Qtr) 41.17
Total Debt (Qtr) 2.68 Mn
Debt/Equity (Qtr) 0.03

About

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 84.97M provide 78.46x coverage of short-term debt 1.08M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 139.16M provides 51.98x coverage of total debt 2.68M, indicating robust asset backing and low credit risk.
  • Tangible assets of 139.16M provide robust 5.50x coverage of other current liabilities 25.31M, indicating strong asset backing.
  • Cash reserves of 84.97M provide robust 1.91x coverage of current liabilities 44.50M, indicating strong short-term solvency.
  • Strong cash position of 84.97M provides 3.36x coverage of other current liabilities 25.31M, indicating excellent liquidity.

Bear case

  • Investment activities of (150000) provide weak support for R&D spending of 46.17M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (80.29M) shows concerning coverage of stock compensation expenses of 12.14M, with a -6.62 ratio indicating potential earnings quality issues.
  • Free cash flow of (80.44M) provides weak coverage of capital expenditures of 150000, with a -536.27 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (59.86M) show weak coverage of depreciation charges of 3.19M, with a -18.78 ratio indicating high capital intensity and potential reinvestment needs.
  • High financing cash flow of 58.53M relative to working capital of 65.27M, which is 0.90x suggests concerning dependence on external funding for operational needs.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,511.45 Bn -1,640.00 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 463.25 Bn 6,757.80 93.16 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 119.13 Bn 32.42 10.16 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.93 Bn 18.33 5.89 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.97 Bn 1,284.81 17.44 3.21 Bn
6 ARGX Argenx Se 47.47 Bn 31.51 24,751.70 -
7 BNTC Benitec Biopharma Inc. 41.27 Bn -986.67 0.00 0.00 Bn
8 INSM INSMED Inc 33.76 Bn -28.52 75.53 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.08 13.39
EV to Cash from Ops. EV/CFO -3.60 23.02
EV to Debt EV to Debt 107.96 789.59
EV to EBIT EV/EBIT -4.83 -11.14
EV to EBITDA EV/EBITDA -4.89 7.05
EV to Free Cash Flow [EV/FCF] EV/FCF -3.59 21.44
EV to Market Cap EV to Market Cap 0.90 72.36
EV to Revenue EV/Rev 5.78 194.41
Price to Book Value [P/B] P/B 3.45 23.19
Price to Earnings [P/E] P/E -5.36 -11.47
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.02
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.15
Interest Coverage Interest Coverage 0.00 856.48
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -3.45 -27.12
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -20.49 747.06
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 73.41 -48.05
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 74.58 -1.94
EBIT Growth (1y) % EBIT 1y % (Qtr) 73.41 -57.64
EBT Growth (1y) % EBT 1y % (Qtr) 73.41 -14.19
EPS Growth (1y) % EPS 1y % (Qtr) 76.02 -30.71
FCF Growth (1y) % FCF 1y % (Qtr) 58.16 -32.52
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 337.75 227.96
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.36 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 1.91 3.79
Current Ratio Curr Ratio (Qtr) 2.47 7.23
Debt to Equity Ratio Debt/Equity (Qtr) 0.03 0.42
Interest Cover Ratio Interest Cover Ratio 0.00 856.48
Times Interest Earned Times Interest Earned 0.00 856.48
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -113.30 -18,509.94
EBIT Margin % EBIT Margin % (Qtr) -119.63 -18,862.18
EBT Margin % EBT Margin % (Qtr) -119.63 -19,783.19
Gross Margin % Gross Margin % (Qtr) 93.30 -8.62
Net Profit Margin % Net Margin % (Qtr) -119.60 -19,732.60